Reports Q4 revenue $91.1M, consensus $91.35M. “Last year, our commercial and financial strength allowed us to deliver significant earnings ...

From ancient remedies to modern natural treatments, discover proven solutions for fever blisters that actually work, ...

In a human cell-based brain model, repetitive physical injuries reactivate the common virus, Herpes Simplex Virus 1 (HSV-1), ...

Detailed price information for Theralase Technologies Inc (TLTFF) from The Globe and Mail including charting and trades.

The overall market of herpes simplex is expected to boost with the expected launch of emerging therapy, increased awareness, and extensive research in the forecast period (2025-2034). LAS ...

Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023Full year revenues increased 473% to $290.5 million versus ...

In these latest experiments, Dr. Coombs evaluated the ability of Ruvidar TM to restrict HSV-1 replication in Vero cells, both by itself and in combination with acyclovir in the absence of ...

Fintel reports that on February 20, 2025, Citigroup initiated coverage of Candel Therapeutics (NasdaqGM:CADL) with a Buy ...

Very early exposure to even a very small dose of herpes simplex virus (HSV) in infant mice can lead to cognitive decline ...

The Centers for Disease Control and Prevention (CDC) estimates that about 45 million people in the United States have genital HSV, with up to a half-million new cases identified each year.

Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the ...

Paris, France, February 20, 2025 – EG 427, a biotechnology company leading the development of pinpoint genetic medicines for prevalent chronic diseases in neurology, announced today the successful ...